Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:33 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 1,666 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Metabolic Complications Clear all

Conditions: Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
Interventions: Renal Denervation (Symplicity Spyral™); Device
Lead sponsor: Medtronic Vascular; Industry
Eligibility: 18 Years and older
Enrollment: 1,899 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 76
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 67 more

Conditions: Kidney Failure, Secondary Hyperparathyroidism, Hyperphosphatemia, Hypercalcemia
Interventions: Calcitriol, Paricalcitol; Drug
Lead sponsor: Winthrop University Hospital; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Mineola, New York

Conditions: Diabetes Complications, Hypoglycemia
Interventions: Fasting; Behavioral
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years to 40 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, End Stage Renal Disease
Interventions: Adipose tissue biopsy; Procedure
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2019
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Diabetic Foot Ulcer, Diabetic Wound, Diabetes Mellitus, Type 2, Diabetic Foot, Diabetes Complications, Peripheral Neuropathy
Interventions: Peer counseling group; Behavioral
Lead sponsor: Casa Colina Hospital and Centers for Healthcare; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: Downey, California • Los Angeles, California • Pomona, California

Conditions: Obesity in Pregnancy, Labor Complication
Interventions: Azithromycin, Placebo; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 15 Years to 45 Years · Female only
Enrollment: 787 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Hyperparathyroidism, Secondary
Interventions: Etelcalcetide; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 891 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 101
States / cities: Birmingham, Alabama • Pine Bluff, Arkansas • Azusa, California + 86 more

Conditions: Postoperative Pain, Pregnancy, Obesity
Interventions: 0.9% Normal Saline, 0.2% Ropivacaine, 0.5% Ropivacaine, 0.75% Ropivacaine; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Primary Hyperoxaluria, Cystinuria, Adenine Phosphoribosyl Transferase Deficiency, Dent Disease
Interventions: Health-related Quality of Life in Rare Kidney Stone Questionnaire; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 5 Years and older
Enrollment: 365 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 2
States / cities: Rochester, Minnesota • New York, New York

Conditions: Gestational Diabetes Mellitus (GDM)
Interventions: Fiber; Dietary Supplement
Lead sponsor: Eastern Virginia Medical School; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Foot Ulcer, Diabetic
Interventions: No intervention; Other
Lead sponsor: Podimetrics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 6,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Somerville, Massachusetts

Conditions: Diabetic Neuropathy
Interventions: Centella asiatica selected triterpenes (CAST), Placebo; Drug · Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Hyperphosphatemia, End-stage Renal Disease
Interventions: ferric citrate; Drug
Lead sponsor: Keryx Biopharmaceuticals; Industry
Eligibility: 19 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Hypophosphatemia, X-linked Hypophosphatemia, Renin-angiotensin System, Left Ventricular Hypertrophy
Interventions: Ang II and Ang-(1-7), FGF23 and klotho; Diagnostic Test
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 2 Years to 24 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Renal Osteodystrophy, Chronic Kidney Diseases, CKD-MBD, Bone Turnover Rate Disorder, Secondary Hyperparathyroidism
Interventions: miRNAseq analysis, Standard treatment for bone disorder; Procedure · Drug
Lead sponsor: Thomas Nickolas; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Lowe Syndrome
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: Male only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetic Nephropathies, Diabetic Glomerulosclerosis
Interventions: There is no intervention; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 100 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 17
States / cities: Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 13 more

Conditions: Gestational Diabetes
Interventions: Glyburide, Continuous glucose monitor; Drug · Device
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 50 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Peritoneal Dialysis Complication, Hyperphosphatemia, Hypoalbuminemia
Interventions: Sucroferric Oxyhydroxide Chewable Tablet; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 80 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Hyperbilirubinemia, Jaundice, Dehydration, Postpartum Depression
Interventions: Home Nurse Visit; Behavioral
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 1 Day to 7 Months
Enrollment: 1,154 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2010
U.S. locations: 2
States / cities: Hershey, Pennsylvania

Conditions: Gestational Diabetes Mellitus
Interventions: Not listed
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 89 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Phenylketonuria
Interventions: Restricted phenylalanine diet; Behavioral
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 0 Years and older · Female only
Enrollment: 572 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1984 – 2000
U.S. locations: 3
States / cities: Los Angeles, California • Chicago, Illinois • Galveston, Texas

Conditions: Gestational Diabetes Mellitus
Interventions: Low Carbohydrate/Conventional, Choosing Healthy Options in Carbohydrate Energy; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: Up to 36 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Short Bowel Syndrome, Malabsorption
Interventions: Relizorb; Device
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 2 Years to 18 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 2
States / cities: Los Angeles, California • Boston, Massachusetts

Search by objective public record fields.

SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN

Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol

Testing Glial Pathways to HAAF in Human Subjects Using Carbon 13 Magnetic Resonance Spectroscopy

Adipose Tissue Function After Pancreas Transplantation

Peer Support for Patients With Diabetic Foot Ulcers

Antibiotic Prophylaxis to Prevent Obesity-Related Induction Complications in Nulliparae at Term 2.0

Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis

Transverse Abdominis Plane (TAP) Block After Cesarean Delivery

Health-related Quality of Life in Rare Kidney Stone

Effect of Fiber Supplementation on the Need for Medication With Gestational Diabetes

Approaches to Foot Complication Prevention: A Survey of Diabetes Educators

Centella Asiatica Selected Triterpenes (CAST) for Diabetic Neuropathy

A Safety and Tolerability Study of Zerenex (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD)

FGF23 and Angiotensin-(1-7) in Hypophosphatemia (GAP)

Precision Medicine Approaches to Renal Osteodystrophy

Genetic Analysis of Oculocerebrorenal Syndrome of Lowe

Transformative Research in Diabetic Nephropathy

Glycemic Profile in Women With Gestational Diabetes Treated With Glyburide

Effect of Velphoro on Serum Phosphate and Albumin in Peritoneal Dialysis Patients

Improving Health Outcomes for New Mothers and Babies

Weight Changes During and After Pregnancy in Women With Gestational Diabetes

Low Phenylalanine Diet for Mothers With Phenylketonuria (PKU)

Trial of Diet in Gestational Diabetes Mellitus: Metabolic Consequences to Mother and Offspring

A 90 Day, Phase 3,Open Labeled Exploratory Study of RELiZORB